Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors

Journal of Clinical Oncology

Volumn 25, Issue 16, 2007, Pages 2274-2280

  Spunt, Sheri L ^a   Freeman III, Burgess B ^a   Billups, Catherine A ^a   McPherson, Valerie ^a   Khan, Raja B ^a   Pratt, Charles B ^a   Stewart, Clinton F ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBAMAZEPINE; LOPERAMIDE; OXALIPLATIN; PLATINUM; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DYSESTHESIA; FEMALE; HUMAN; HYPONATREMIA; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOSITIS; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; THROAT DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; NEOPLASM; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 34250176208     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.2388     Document Type: Article

References (51)

1. Saris CP, van de Vaart PJ, Rietbroek RC, et al: In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763-2769, 1996
2. Woynarowski JM, Chapman WG, Napier C, et al: Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777, 1998
3. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
4. Page JD, Husain I, Sancar A, et al: Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29:1016-1024, 1990
5. Gibbons GR, Page JD, Mauldin SK, et al: Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res 50:6497-6501, 1990
6. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805, 1993
7. Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976, 1993
8. Tashiro T, Kawada Y, Sakurai Y, et al: Antitumor activity of a new platinum complex, oxalato (trans-I-1,2-diaminocyclohexane) platinum (II): New experimental data. Biomed Pharmacother 43:251-260, 1989
9. Riccardi A, Ferlini C, Meco D, et al: Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 35:86-90, 1999
10. Dunn TA, Schmoll HJ, Grunwald V, et al: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 15:109-114, 1997
11. Faivre S, Chan D, Salinas R, et al: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66:225-237, 2003
12. Woynarowski JM, Faivre S, Herzig MC, et al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920-927, 2000
13. Goodisman J, Hagrman D, Tacka KA, et al: Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 57:257-267, 2006
14. Monti E, Gariboldi M, Maiocchi A, et al: Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: A quantitative structure-activity relationship approach. J Med Chem 48:857-866, 2005
15. Chollet P, Bensmaine MA, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070, 1996
16. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886, 1996
17. Scheeff ED, Briggs JM, Howell SB: Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56:633-643, 1999
18. Vaisman A, Varchenko M, Umar A, et al: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585, 1998
19. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303, 1990
20. Webster RG, Brain KL, Wilson RH, et al: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146:1027-1039, 2005
21. Wilson RH, Lehky T, Thomas RR, et al: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774, 2002
22. Mathe G, Kidani Y, Triana K, et al: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (I-OHP). Biomed Pharmacother 40:372-376, 1986
23. Desrame J, Broustet H, Darodes de Tailly P, et al: Oxaliplatin-induced haemolytic anaemia. Lancet 354:1179-1180, 1999
24. Extra JM, Marty M, Brienza S, et al: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22, 1998
25. Massari C, Brienza S, Rotarski M, et al: Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164, 2000
26. Pectasides D, Pectasides M, Farmakis D, et al: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: A phase II study. Gynecol Oncol 95:165-172, 2004
27. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
28. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
29. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
30. Garufi C, Nistico C, Brienza S, et al: Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study. Ann Oncol 12:179-182, 2001
31. Zori Comba A, Blajman C, Richardet E, et al: A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 37:1006-1013, 2001
32. Baum ES, Gaynon P, Greenberg L, et al: Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group report. Cancer Treat Rep 63:1621-1627, 1979
33. Baum ES, Gaynon P, Greenberg L, et al: Phase II trial of cisplatin in refractory childhood cancer: Children's Cancer Study Group report. Cancer Treat Rep 65:815-822, 1981
34. Pratt CB, Hayes A, Green AA, et al: Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: A phase II study. Cancer Treat Rep 65:1021-1026, 1981
35. Carli M, Perilongo G, di Montezemolo LC, et al: Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: A report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 71:525-527, 1987
36. Ettinger LJ, Gaynon PS, Krailo MD, et al: A phase II study of carboplatin in children with recurrent or progressive solid tumors: A report from the Children's Cancer Group. Cancer 73:1297-1301, 1994
37. Gaynon PS, Ettinger LJ, Baum ES, et al: Carboplatin in childhood brain tumors: A Children's Cancer Study Group phase II trial. Cancer 66:2465-2469, 1990
38. Sexauer CL, Khan A, Burger PC, et al: Cisplatin in recurrent pediatric brain tumors: A POG phase II study. Cancer 56:1497-1501, 1985
39. Frappaz D, Michon J, Hartmann O, et al: Etoposide and carboplatin in neuroblastoma: A French Society of Pediatric Oncology phase II study. J Clin Oncol 10:1592-1601, 1992
40. Knight KR, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596, 2005
41. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, et al: Persisting renotubular sequelae after cisplatin in children and adolescents. Am J Nephrol 11:127-130, 1991
42. Calvert H, Judson I, van der Vijgh WJ: Platinum complexes in cancer medicine: Pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv 17:189-217, 1993
43. Graham MA, Lockwood GF, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000
44. Morrison JG, White P, McDougall S, et al: Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: Application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24:1-10, 2000
45. D'Argenio D, Schumitzky A: ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulations Resource, University of Southern California, 1990
46. Grolleau F, Gamelin L, Boisdron-Celle M, et al: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293-2297, 2001
47. Gamelin L, Boisdron-Celle M, Delva R, et al: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10: 4055-4061, 2004
48. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16:2739-2744, 1998
49. Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9:105-108, 1998
50. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
51. Fouladi M, Blaney SM, Poussaint TY, et al: Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: A Pediatric Brain Tumor Consortium study. Cancer 107:2291-2297, 2006